Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -461.79%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-238.67%
RETURN ON EQUITY (ROE) AVG 3Y
-94.70%
RETURN ON EQUITY (ROE) AVG 5Y
-54.02%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lantern Pharma Inc.
Market Cap
$13.01M
Return on Equity (ROE)
N/A
TTM Avg
-238.67%
3Y Avg
-94.70%
5Y Avg
-54.02%
Market Cap
$12.86M
Return on Equity (ROE)
-74.73%
TTM Avg
-265.78%
3Y Avg
-138.63%
5Y Avg
-109.18%
Market Cap
$12.60M
Return on Equity (ROE)
N/A
TTM Avg
-162.71%
3Y Avg
-135.96%
5Y Avg
-98.83%
Market Cap
$12.56M
Return on Equity (ROE)
N/A
TTM Avg
-201.97%
3Y Avg
-21.23%
5Y Avg
365.72%
Market Cap
$12.98M
Return on Equity (ROE)
-810.41%
TTM Avg
-174.22%
3Y Avg
-126.94%
5Y Avg
-100.46%
Market Cap
$12.37M
Return on Equity (ROE)
-97.47%
TTM Avg
-90.15%
3Y Avg
-205.18%
5Y Avg
-136.35%
Market Cap
$13.48M
Return on Equity (ROE)
-39.76%
TTM Avg
-59.76%
3Y Avg
-51.18%
5Y Avg
-40.48%
Market Cap
$11.81M
Return on Equity (ROE)
-37052.06%
TTM Avg
-237.80%
3Y Avg
-258.91%
5Y Avg
-310.30%
Market Cap
$13.89M
Return on Equity (ROE)
-69.47%
TTM Avg
-55.64%
3Y Avg
-44.95%
5Y Avg
-41.56%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | $13.01M | N/A | -238.67% | -94.70% | -54.02% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.86M | -74.73% | -265.78% | -138.63% | -109.18% |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | N/A | -162.71% | -135.96% | -98.83% |
| Dare Bioscience, Inc. (DARE)vs › | $12.56M | N/A | -201.97% | -21.23% | 365.72% |
| Passage Bio, Inc. (PASG)vs › | $12.98M | -810.41% | -174.22% | -126.94% | -100.46% |
| IRIDEX Corporation (IRIX)vs › | $12.37M | -97.47% | -90.15% | -205.18% | -136.35% |
| Optimi Health Corp. (OPTH)vs › | $13.48M | -39.76% | -59.76% | -51.18% | -40.48% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.81M | -37052.06% | -237.80% | -258.91% | -310.30% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.89M | -69.47% | -55.64% | -44.95% | -41.56% |
| IN8bio, Inc. (INAB)vs › | $13.89M | -101.66% | -140.38% | -131.64% | -101.94% |
ROE
N/A
ROA
-216.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -461.79% |
| 2025-12-31 | -262.00% |
| 2025-09-30 | -197.36% |
| 2025-06-30 | -153.71% |
| 2025-03-31 | -118.48% |
| 2024-12-31 | -98.08% |
| 2024-09-30 | -71.78% |
| 2024-06-30 | -57.38% |
| 2024-03-31 | -49.03% |
| 2023-12-31 | -39.02% |
| 2023-09-30 | -33.38% |
| 2023-06-30 | -29.55% |
| 2023-03-31 | -26.64% |
| 2022-12-31 | -25.45% |
| 2022-09-30 | -24.43% |
| 2022-06-30 | -26.54% |
| 2022-03-31 | -21.48% |
| 2021-12-31 | -17.27% |
| 2021-09-30 | -15.47% |
| 2021-06-30 | -11.76% |
| 2021-03-31 | -9.65% |
| 2020-12-31 | -29.99% |
| 2020-09-30 | -17.09% |
| 2020-06-30 | -11.43% |
| 2020-03-31 | -456.97% |
| 2019-12-31 | -257.42% |
